Company intelligence / Profile preview
Beiersdorf AG
Hamburg, Hamburg, Germanybeiersdorf.com ↗
- Ownership
- Public · BEI
- Employees
- ~20000
- Development stage
- Commercial
01
Overview
The company has several discontinued or pending clinical programs including Brefanolol for hypertension (discontinued), BDF-9167 for heart failure (discontinued), BDF-9198 for heart failure (pending), and Ecastolol for hypertension (pending)[10].
- Therapeutic areas
- Cardiovascular
- Modalities
- Topical formulationsTransdermal patchesOral filmsSmall molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Historical partnership with Lehn & Fink (US)
04
Financials
- Market cap
- $20.6B
- Total revenue
- $11B
- Enterprise value
- $17.9B
Beyond the preview
Go deeper on Beiersdorf AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beiersdorf AG.